公开(公告)号：US11352322B2

公开(公告)日：2022-06-07

申请号：US16098341

申请日：2017-05-08

申请人： Jubilant Epicore LLC

发明人： Sridharan Rajagopal ,  Mahanandeesha S. Hallur ,  Purushottam Dewang ,  Kannan Murugan ,  Durga Prasanna Kumar C. H. ,  Pravin Iyer ,  Chandrika Mulakala ,  Dhanalakshmi Sivanandhan ,  Sreekala Nair ,  Mohd Zainuddin ,  Subramanyam Janardhan Tantry ,  Chandru Gajendran ,  Sriram Rajagopal

IPC分类号： C07D205/12 ,  A61P35/00 ,  C07C235/56 ,  C07C237/20 ,  C07C259/08 ,  C07D205/04 ,  C07D211/26 ,  C07D217/18 ,  C07D231/12 ,  C07D233/64 ,  C07D239/26 ,  C07D249/04 ,  C07D401/04 ,  C07D401/14 ,  C07D413/12 ,  C07D413/14 ,  C07D417/06 ,  C07D417/12 ,  C07D487/04 ,  C07D495/04 ,  C07D209/44 ,  A61K45/06

摘要： The present disclosure describes novel compounds of the general Formula (I), their analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites, and prodrugs thereof. These compounds can inhibit both LSD and HDAC and are useful as therpeautic or ameliorating agent for diseases that are involved in cellular growth such as malignant tumors, schizophrenia, Alzheimer's disease, parkinson's disease and the like.